Table 1.
Sample | Origin | T-2 | HT-2 | 3-ADON | DON | NIV | DAS | NEO | BEA | 15-AS |
---|---|---|---|---|---|---|---|---|---|---|
SP1 | Spain | ND | ND | ND | 61.21 | ND | ND | ND | ND | 6.25 |
SP2 | Spain | 2123.58 | 7.5 | 423.45 | 73.1 | ND | ND | ND | ND | 4.07 |
SP3 | Spain | ND | ND | ND | ND | ND | ND | ND | ND | ND |
SP4 | Spain | ND | ND | ND | ND | ND | ND | ND | ND | ND |
SP5 | Spain | ND | ND | ND | 14.77 | ND | ND | ND | ND | ND |
SP6 | Spain | ND | ND | ND | ND | ND | ND | ND | ND | ND |
SP7 | Spain | ND | ND | ND | ND | ND | ND | ND | ND | ND |
SP8 | Spain | ND | ND | ND | ND | ND | ND | ND | ND | ND |
SP9 | Spain | ND | ND | ND | ND | ND | ND | ND | ND | ND |
SP10 | Spain | ND | ND | ND | 15.37 | ND | ND | ND | ND | ND |
SP11 | Spain | ND | ND | ND | ND | ND | ND | ND | ND | ND |
SP12 | Spain | ND | ND | ND | 10.79 | ND | ND | ND | ND | ND |
UK1 | UK | ND | ND | ND | ND | 2276.19 | 15.29 | ND | 98.95 | 86.60 |
UK2 | UK | ND | ND | ND | 63.42 | ND | ND | ND | 10.43 | ND |
UK3 | UK | ND | ND | <LOQ | ND | 424.65 | 0.69 | ND | 1266.00 | 54.75 |
UK4 | UK | 1400.23 | ND | ND | ND | ND | ND | ND | 44.03 | ND |
UK5 | UK | ND | ND | <LOQ | ND | 689.26 | ND | ND | 2.44 | ND |
UK6 | UK | ND | ND | <LOQ | ND | ND | ND | 5.29 | ND | ND |
UK7 | UK | 391.84 | ND | ND | ND | 233.27 | ND | ND | 456.30 | 5.23 |
DON, deoxynivalenol; 3-ADON, 3-acetylDON; NIV, nivalenol; DAS, diacetoxyscirpenol; NEO, neosolaniol; BEA, beauvericin; 15-AS, 15-acetoxyscirpenol; LOQ, limit of quantification; LOD, limit of detection; <LOQ, LOD < X < LOQ; ND, not detected.